Table 1 Clinicopathological characteristics of the control group and study group invasive micropapillary carcinoma
Characteristics | CgIMPC (n = 163) (n,%) | SgIMPC (n = 2299) (n,%) | P value |
|---|---|---|---|
Age at diagnosis (years) | <0.001 | ||
≤50 | 94 (58) | 969 (42) | |
>50 | 69 (42) | 1330 (58) | |
Tumor size (mm) | 0.012 | ||
≤20 | 26 (17) | 591 (37) | |
20–50 | 102(68) | 1385 (62) | |
>50 | 22 (15) | 255 (11) | |
IMPC proportion | <0.001 | ||
≤25% | 32 (20) | 1148 (50) | |
26–50% | 39 (24) | 560 (25) | |
51–75% | 38 (23) | 156 (7) | |
>75% | 54 (33) | 412 (18) | |
No of LNM | <0.01 | ||
0 | 26 (16) | 722 (32) | |
1–3 | 30 (19) | 563 (25) | |
≥4 | 105 (65) | 982 (43) | |
TNM stage | 0.156 | ||
I | 17 (11) | 372 (16) | |
II | 70 (43) | 924 (41) | |
III–IV | 74 (46) | 964 (43) | |
Histologic grade | 0.379 | ||
I | 32 (20) | 413 (18) | |
II | 88 (54) | 1398 (62) | |
III | 42 (26) | 454 (20) | |
ER | <0.001 | ||
− | 52 (32) | 318 (15) | |
+ | 111 (68) | 1818 (85) | |
PR | <0.001 | ||
− | 59 (36) | 473 (22) | |
+ | 104 (64) | 1658 (78) | |
HER-2 | 0.390 | ||
0/1+ | 96 (60) | 1341 (63) | |
2+ | 53 (33) | 606 (29) | |
3+ | 11 (7) | 184 (9) | |
LVI | 0.030 | ||
− | 76 (47) | 1746 (55) | |
+ | 87 (53) | 530 (45) | |
LNM with ECE | 0.163 | ||
− | 103 (63) | 1507 (68) | |
+ | 60 (37) | 694 (32) | |
Local regional recurrence | 20 (12) | 56 (5) | <0.001 |
Distant metastasis | 68 (42) | 96 (9) | <0.001 |
Died of disease | 76 (47) | 89 (8) | <0.001 |
Surgery type | 0.001 | ||
Breast-conserving surgery/Lumpectomy | 5 (3) | 16 (1) | |
Mastectomy | 158 (97) | 2283 (99) | |
Chemotherapy (adjuvant/ neoadjuvant) | 0.516 | ||
0 | 13 (8) | 153 (7) | |
1 | 150 (92) | 2146 (93) | |
Radiation therapy | 0.206 | ||
0 | 69 (42) | 1060 (46) | |
1 | 94 (58) | 1239 (54) | |
Endocrine therapy | <0.001 | ||
0 | 72 (47) | 308 (15) | |
1 | 80 (53) | 1794 (85) |
